Five Under 5: Top Oncology Videos for the Week of 4/27

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC: S. Daniel Haldar, MD

S. Daniel Haldar, MD, of The University of Texas MD Anderson Cancer Center, discussed data from a nonrandomized, open-label, single-center pilot study evaluating the safety and feasibility of a personalized neoantigen vaccine NeoAg-VAX with (n = 15) or without (n = 13) pembrolizumab (Keytruda) in patients with microsatellite-stable metastatic colorectal cancer. Data shared during the 2025 AACR Annual Meeting showed that the vaccine alone led to an objective response rate (ORR) of 7.7%, a disease control rate (DCR) of 61.5%, a median progression-free survival (PFS) of 2.9 months, and a median overall survival (OS) of 29 months. The vaccine paired with pembrolizumab led to an ORR of 6.7%, a DCR of 53.3%, a median PFS of 2.8 months, and a median OS of 24 months. Toxicities associated with the vaccine were all grade 1 or 2, with the most frequent being injection site burning, injection site pain, and myalgia.

Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies: Pietro Scilipoti, MD

Pietro Scilipoti, MD, of Ospedale San Raffaele, discusses the importance of incorporating life expectancy assessments into prostate cancer treatment decisions. He presented findings at the 2025 AUA Annual Meeting showing that comorbidity-based models offer more accurate risk evaluations than chronological age alone. Scilipoti emphasized that current guidelines lack validated tools for life expectancy assessment, which can lead to overtreatment or undertreatment. He advocates for prospective validation of these models and their inclusion in clinical trial design to better tailor treatments to patient risk profiles.

Effects of NSD2 Overexpression in Multiple Myeloma: Amin Sobh, PhD

Amin Sobh, PhD, of the University of Florida College of Medicine, discussed findings from a study investigating the role that NSD2 plays in modulating immune surveillance in multiple myeloma. It is known that NSD2 is overexpressed in 15% of patients with multiple myeloma because of the t(4;14) translocation. Data shared during the 2025 AACR Annual Meeting suggested that NSD2 overexpression in this disease could suppress immune surveillance through downregulation of MHC-II expression in antigen-presenting immune cells. Moreover, increased IL10 production by NSD2 overexpressing multiple myeloma cells may underlie MHC-II suppression. Lastly, the effect of NSD2 overexpression and inhibition on immune microenvironment modulation of the bone marrow will be explored in immunocompetent mouse models of multiple myeloma.

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC: Chad Tang, MD

Chad Tang, MD, of The University of Texas MD Anderson Cancer Center, shared data from a phase 2 trial (NCT03575611) evaluating metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma. The trial included patients with clear cell histology, with up to 5 metastases, who had not previously received systemic therapy or were off previous systemic therapy for longer than a month. The co-primary end points were PFS and systemic therapy-free survival (STFS). The median PFS was 18 months (95% CI, 15-22) and the median STFS was 34 months (95% CI, 28-54). Moreover, the median overall survival (OS) was not reached, and the 3-year OS rate was 87%. Further trials are required to further evaluate this approach vs doublet systemic therapy.

Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC: Joseph Jacob, MD, MCR

Joseph Jacob, MD, MCR, of SUNY Upstate Medical University, discusses TAR-200 as a promising intravesical therapy that delivers sustained doses of gemcitabine directly to the bladder, potentially improving treatment outcomes for patients with high-risk, non–muscle-invasive bladder cancer. He presented phase 2b SunRISe-1 trial (NCT04640623) data at the 2025 AUA Annual Meeting, showing high complete response rates and durable outcomes in BCG-unresponsive patients. Jacob highlighted TAR-200’s potential to shift the standard of care by offering a bladder-sparing alternative to radical cystectomy. He also noted that this device-based platform could pave the way for delivering other intravesical agents in the future.